Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281202 · ClinicalTrials.gov registry record · Phase 2
Vigabatrin for the Treatment of Cocaine Dependency
A Phase 2 study of Cocaine Dependence and Cocaine Addiction, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 13
- Study locations
NCT01281202 is a Phase 2 study of Cocaine Dependence and Cocaine Addiction that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 207 participants, below the 293-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (29% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT01281202, a Phase 2 study of Cocaine Dependence and Cocaine Addiction, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 13
- Study locations
Study Summary
The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects treated with placebo in addition to counseling.
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG Vigabatrin
Study Locations (13)
California
- Matrix Institute on Addictions - Los Angeles
- Friends Research Institute - Torrance
Texas
- Pillar Clinical Research, LLC - Dallas
- University of Texas Health Science Center at Houston - Houston
Colorado
- VA Medical Center - Denver
Florida
- University of Miami School of Medicine - Miami
Illinois
- NeuroPsychiatric Research & Practice Assoc., Ltd. - Oak Brook
Maryland
- Mountain Manor Treatment Center @ Baltimore - Baltimore
Massachusetts
- Boston University School of Medicine - Boston
New Mexico
- Pacific Institute for Research and Evaluation - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281202
The ClinicalTrials.gov registry entry for NCT01281202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (29% lower). The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT01281202 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT01281202 about?
NCT01281202 is a clinical study titled "Vigabatrin for the Treatment of Cocaine Dependency". The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects t...
What is the current status of trial NCT01281202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2011-01. Estimated completion is 2012-12.
What conditions does trial NCT01281202 study?
This clinical trial studies the following conditions: Cocaine Dependence, Cocaine Addiction.
What interventions are being tested in trial NCT01281202?
The interventions under investigation include: Matching Placebo (DRUG), Vigabatrin (DRUG).
Who is sponsoring clinical trial NCT01281202?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01281202 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.